Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsHoward Feldman, MD, FRCPC, FAAN (Neurology)
Professor AdjunctAbout
Copy Link
Research
Copy Link
Overview
Medical Research Interests
Dementia; Information Science; Named Groups
ORCID
0000-0002-4435-0913
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
Research Interests
Research topics Howard Feldman is interested in exploring.
James Brewer
Godfrey Pearlson, MA, MBBS
Harlan Krumholz, MD, SM
271Publications
12,903Citations
Publications
2026
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Cummings J, Atri A, Sano M, Zetterberg H, Scheltens P, Knop F, Johannsen P, Wichmann C, Abschneider R, Leon T, Feldman H. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet 2026 PMID: 41865758, DOI: 10.1016/s0140-6736(26)00459-9.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEarly Alzheimer's diseaseSafety of oral semaglutideCDR-SB scoresFlexible dosingBaseline to weekOral semaglutideCDR-SBAlzheimer's diseaseClinical Dementia Rating-SumPlacebo-controlled phase 3 trialDose of study drugTreatment-emergent adverse eventsMild cognitive impairmentRandomised participantsPlacebo-controlled trialPhase 3 trialConsistent with studiesCognitive impairmentSmall vessel pathologyReduced riskReal-world studyNegative clinical outcomesSymptomatic Alzheimer's diseaseType 2 diabetesDouble-blindOpportunities and Alternative Approaches for Improving Language Outcomes in Young Children.
Feldman H, Marchman V. Opportunities and Alternative Approaches for Improving Language Outcomes in Young Children. 2026, 157 PMID: 41833319, DOI: 10.1542/peds.2025-075539.Peer-Reviewed Original ResearchAltmetricValidation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial
Duehring J, Jacobs D, Salmon D, MacKelfresh A, Revta C, Meyer A, Schaeffer M, Schell-Mader S, Wassmann T, Wenzkowski C, Feldman H, Edland S, Group A. Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial. The Journal Of Prevention Of Alzheimer's Disease 2026, 13: 100531. PMID: 41830756, PMCID: PMC12996941, DOI: 10.1016/j.tjpad.2026.100531.Peer-Reviewed Original ResearchAltmetricConceptsCDR-SBOutcome measuresClinical Dementia Rating SumComposite measureStandard power calculationsClinical outcome measuresRandomized Controlled TrialsMild cognitive impairmentEarly Alzheimer's diseaseLinear mixed-effects modelsAlzheimer's diseaseSecondary analysisMixed-effects modelsSample size requirementsCognitive impairmentNeuropsychological test dataFunctional outcomesEfficiency of clinical trialsTrial efficiencyRate sumAD populationSample sizePower calculationsTrialsRandomized clinical trial dataA path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Reiman E, Alexander R, Langbaum J, Aisen P, Ashton N, Atri A, Barbarino P, Byrd G, Feldman H, Fowler N, Ghisays V, Grill J, Hassenstab J, Heaton G, Herring W, Jack C, Johnson S, Karlawish J, Keach N, Kivipelto M, Krumholz H, Largent E, MaGee-Rodgers T, McDade E, Mielke M, Molina-Henry D, Petersen R, Rabinovici G, Ritchie C, Schindler S, Sperling R, Suárez-Calvet M, Vradenburg G, Weiner M, Welsh-Bohmer K, Zetterberg H, Zuendel M, Mattke S, Cummings J. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. The Lancet Neurology 2026, 25: 268-278. PMID: 41722593, DOI: 10.1016/s1474-4422(25)00483-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsSlow cognitive declineBiomarkers of Alzheimer's diseasePrimary prevention therapyAlzheimer's diseaseClinical manifestation of Alzheimer's diseaseManifestation of Alzheimer's diseaseCognitive AssessmentInsurance coverageCognitive declineCognitive impairmentBlood testsPreventive therapyAmyloid plaquesClinical manifestationsDisease-modifying treatmentsDrug treatmentNegative testPeopleAlzheimer's disease therapyApprovalDiseaseAlzheimerAntibody therapyParticipantsDisease-modifyingRelationships between fine memory discrimination and tau burden in two independent cohorts of older adults
Fenton L, Aslanyan V, Jacobs D, Salmon D, Brewer J, Rissman R, Shadyab A, Harrison T, Evans A, LaCroix A, Feldman H, Baker L, Pa J. Relationships between fine memory discrimination and tau burden in two independent cohorts of older adults. Neuropsychologia 2026, 224: 109393. PMID: 41672403, DOI: 10.1016/j.neuropsychologia.2026.109393.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsMnemonic Similarity TaskMemory discriminationHippocampal volumeLogical memoryLower hippocampal volumeHigher tauOlder adultsMnemonic similarity task performanceAssociated with higher tauMedial temporal lobeTraditional memory testsHippocampal integrityMemory testBrain measuresDiscrimination taskAD prevention trialsTemporal lobeAmnestic MCICognitive AssessmentSimilarity taskHippocampalCohort of older adultsAmyloid burdenAmyloid PETMemoryGenetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference.
Field T, Morton S, Brossard-Racine M, Cohen S, Feldman H, Chung A, Newburger J, Puder R, Gurvitz M, Cassidy A. Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference. Journal Of The American Heart Association 2026, 15: e042617. PMID: 41553060, PMCID: PMC12919480, DOI: 10.1161/jaha.125.042617.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsBrain healthCongenital heart diseaseRoutine assessmentGene-environment interactionsHeart diseasePsychological outcomesClinical carePsychiatric riskSurgical carePsychiatric sequalaeMultidisciplinary collaborative effortMultidisciplinary expertsNeuroimaging protocolsHealthKnowledge gapsConsensus statementRisk factorsAssessment of brain healthAdultsCareBrainCollaborative effortsRiskResearch cycleRisk modelBaseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease
Scheltens P, Atri A, Feldman H, Zetterberg H, Sano M, Johannsen P, Colombo T, Bardtrum L, Jeppesen R, Hansen C, Cummings J. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2026, 12: e70200. PMID: 41522368, PMCID: PMC12789876, DOI: 10.1002/trc2.70200.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSafety of semaglutidePhase 3 trialBaseline characteristicsLonger-term efficacyRandomized Controlled TrialsGlucagon-like peptide-1 receptor agonist semaglutidePlacebo-controlled phase 3 trialInclusion criteriaClinical Dementia RatingPrimary readoutBaseline characteristics of participantsProtocol inclusion criteriaDouble-blindOral semaglutideSmall vessel pathologyVessel pathologyAlzheimer's diseaseInhibitor useSymptomatic Alzheimer's diseaseAge of participantsParallel-groupDisease-modifying treatmentsTreatment characteristicsSemaglutideTrial population
2025
Family Navigation Engagement and Outcomes for Children With a New Autism Diagnosis
Lin I, Morgan A, Herringshaw A, Lopez N, Deras M, Feldman H. Family Navigation Engagement and Outcomes for Children With a New Autism Diagnosis. Journal Of Autism And Developmental Disorders 2025, 1-11. PMID: 41313578, DOI: 10.1007/s10803-025-07168-1.Peer-Reviewed Original ResearchAltmetricConceptsSemi-structured sessionsAutism-specific servicesFamily characteristicsEngagement ratesFamilies of childrenLikelihood of childrenDescriptive cohort studyEligible familiesService receiptMedicaid recipientsBlack/African AmericanService accessDescriptive statisticsCohort studyBrief contactsConclusionAbout halfFamily demographicsRegression analysisSessionsSpanish-EnglishAutism diagnosisServicesEnrollmentEngagementFamilyCognitive heterogeneity in mild cognitive impairment due to Alzheimer's disease pathology.
Chen S, Salmon D, Feldman H, Messer K, Bondi M, Xu D, Qiu Y, Jacobs D. Cognitive heterogeneity in mild cognitive impairment due to Alzheimer's disease pathology. Neural Regeneration Research 2025, 21: 3779-3787. PMID: 41169220, DOI: 10.4103/nrr.nrr-d-25-00308.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCognitive impairmentMild cognitive impairmentCognitive heterogeneityCognitive subtypesCognitive profileAlzheimer's diseaseNeuropsychological test dataNon-memory measuresPattern of impairmentPattern of performanceNon-memory testsTypical groupMild Cognitive Impairment SubtypesRate of clinical declineCognitive impairment subtypesMild cognitive impairment due to Alzheimer’s diseaseImpairment subtypesCognitive variablesMemory testCognitive domainsMagnetic resonance imaging volumetric measurementsBrain regionsCerebrospinal fluid biomarkersCognitive testsBrain volumeSeeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method
Dodge H, Chen L, Wu C, Cutter G, Bowman G, Feldman H, Arnold S. Seeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method. Alzheimer's & Dementia 2025, 21: e70787. PMID: 41122812, PMCID: PMC12541280, DOI: 10.1002/alz.70787.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPre-post changesSample sizeStatistical powerPlasma biomarkersBiomarker assessmentBetween-subject variabilityClinical trialsCognitive testsSurrogate outcomesEarly-phase trial designsEarly-phase trialsFollow-up periodTrial designLead-InRecruitment burdenParallel designStudy periodSlim designParallel-group designWithin-individual variabilityPlacebo effectParallel-groupPost-treatment periodMechanism of actionSingle-arm
Get In Touch
Copy Link